Suppr超能文献

医疗保险和双重资格受益人的结肠癌治疗费用。

Colon cancer treatment costs for Medicare and dually eligible beneficiaries.

作者信息

Luo Zhehui, Bradley Cathy J, Dahman Bassam A, Gardiner Joseph C

机构信息

Michigan State University, Department of Epidemiology, East Lansing, MI 48824, USA.

出版信息

Health Care Financ Rev. 2010 Fall;31(1):35-50.

Abstract

To estimate the cost attributable to colon cancer treatment 1 year after diagnosis by cancer stage, comorbidity, treatment regimen, and Medicaid eligibility, we extracted an inception cohort of colon cancer patients aged 66 and older diagnosed between 1997 and 2000 from the Michigan Tumor Registry. Patients were matched to non-cancer control subjects in the Medicare Denominator file. We used the difference-in-differences method to estimate costs attributable to cancer, controlling for costs prior to diagnosis. The mean total colon cancer cost per Medicare patient was $29,196. The method can be applied to longitudinal data to estimate long term costs of cancer from inception where incident patients are identified from a tumor registry.

摘要

为了根据癌症分期、合并症、治疗方案和医疗补助资格来估算结肠癌确诊1年后的治疗费用,我们从密歇根肿瘤登记处提取了一组起始队列,这些患者为1997年至2000年间确诊的66岁及以上的结肠癌患者。患者与医疗保险分母文件中的非癌症对照对象进行匹配。我们使用差异中的差异方法来估算癌症导致的费用,并控制诊断前的费用。每位医疗保险患者的结肠癌平均总费用为29,196美元。该方法可应用于纵向数据,以从肿瘤登记处识别出的发病患者开始估算癌症的长期费用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2256/4195068/9726c6ccaa59/hcfr-31-01-035-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验